Soleus Capital Management L.P. Grows Holdings in Pharvaris (NASDAQ:PHVS)

Soleus Capital Management L.P. increased its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 36.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 814,652 shares of the company's stock after acquiring an additional 216,483 shares during the quarter. Soleus Capital Management L.P. owned about 1.56% of Pharvaris worth $15,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Pharvaris in the 4th quarter worth approximately $64,000. Barclays PLC purchased a new stake in shares of Pharvaris in the 3rd quarter worth approximately $106,000. KLP Kapitalforvaltning AS bought a new position in Pharvaris during the 4th quarter valued at approximately $111,000. Finally, Point72 Asset Management L.P. bought a new position in Pharvaris during the 4th quarter valued at approximately $152,000.

Pharvaris Stock Up 4.1%

NASDAQ:PHVS opened at $16.56 on Monday. The stock has a market cap of $865.92 million, a price-to-earnings ratio of -5.91 and a beta of -2.85. The company's 50 day moving average price is $15.38 and its 200-day moving average price is $17.58. Pharvaris has a 52 week low of $11.51 and a 52 week high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). As a group, sell-side analysts anticipate that Pharvaris will post -2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

PHVS has been the topic of several analyst reports. Cantor Fitzgerald dropped their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. JMP Securities lifted their price target on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.